• Events Calendar
  • Biomarkers
    • Biomarker Analysis
    • Biomarker Identification & Validation
    • Diagnostics Development
    • Translational & Clinical Development
  • Multi-Omics
    • Clinical Diagnostics & Liquid Biopsy
    • Data Analysis, Integration & AI
    • Genome Editing
    • NGS
    • Omics
    • Single Cell
  • Spatial Biology
    • Spatial Application in Therapeutics
    • Spatial Data Analysis
    • Spatial Tools, Technologies & Imaging
    • News
    • Market Insight
    • Technology Spotlight
    • Thought Leadership
Register Sign In
  • Events Calendar
  • Biomarkers
      Biomarker Analysis
      Biomarker Identification & Validation
      Diagnostics Development
      Translational & Clinical Development
  • Multi-Omics
      Clinical Diagnostics & Liquid Biopsy
      Data Analysis, Integration & AI
      Genome Editing
      NGS
      Omics
      Single Cell
  • Spatial Biology
      Spatial Application in Therapeutics
      Spatial Data Analysis
      Spatial Tools, Technologies & Imaging
  • Format
      News
      Market Insight
      Technology Spotlight
      Thought Leadership
    Search
Sign In
Thought Leadership Biomarkers |

Making Precision Oncology the Standard Worldwide - An Interview with the Precision Cancer Consortium

On-Demand
August 13, 2025
|
10:00 UK Time
|
Event lasts 20m
Gabriele Allegri

Gabriele Allegri

Vice President for Global Commercial Precision Medicine

Johnson & Johnson Innovative Medicine

John Longshore

John Longshore

Head of Scientific Affairs for Global Oncology Diagnostics

AstraZeneca

Format: 17 Minute Interview

Register free to attend thought leadership

Do you have a question you’d like Gabriele Allegri, John Longshore to answer during the session?

Register and ask
Related posts
Making Precision Oncology the Standard Worldwide - An Interview with the Precision Cancer Consortium

Making Precision Oncology the Standard Worldwide - An Interview with the Precision Cancer Consortium

Gabriele Allegri Johnson & Johnson Innovative Medicine
John Longshore AstraZeneca
Biomarkers
Aug, 2025
Interview with Viola Heinzelmann Schwarz on the Swiss Tumour Profiler (TuPro) study and OV Precision trial

Interview with Viola Heinzelmann Schwarz on the Swiss Tumour Profiler (TuPro) study and OV Precision trial

Viola Heinzelmann Schwarz University Hospital Basel
Biomarkers
Aug, 2025
How Translational Research Can Impact the Development of Precision Medicine

How Translational Research Can Impact the Development of Precision Medicine

Mohamed Hassanein Pfizer
Daniel Strasser Idorsia
Biomarkers
Jul, 2025
Upcoming events
11
Sep
Harnessing Multi-Omics for Next-Generation Drug Development

Online

Join Tom Lanz, Senior Director of Multi-Omics and Biomarkers, Pfizer to discuss how multi-omics is transforming drug development & the key opportunities and challenges.

30
Sep
Biomarkers & Precision Medicine 2025

In-Person

Europe's flagship event for biomarker innovation returns, advancing drug discovery, development, clinical trials, and precision medicine.

Register for free to view

  • Quickly grasp the key takeaways from cutting-edge biomed research with our bite-sized 5-minute video summaries, before diving into the full presentations from leaders in the industry.

  • From cutting-edge discoveries to real-world applications, see how new research can impact your work, from the lab to commercialisation.

  • Join a community of next-gen scientists, academics and researchers, stay connected, and engage with the latest innovations shaping the future of biomedicine.

Register Free

Already registered? Sign In.

  • Events
    About Us
    Contact Us
    FAQ
    Privacy Policy
    Terms of Use
    Cookie Policy
  • Biomarkers
    Multi-Omics
    Spatial Biology
  • Discovery & Development
    NextGen Biomed
    Precision Medicine
    Oxford Global
© 2025 Oxford Global Ltd. All rights reserved.
Designed & built by Standfirst

You're just a click away

To access our site, please accept the Terms of Use - our full terms of use are available below.
Full Terms of Use

By rejecting you won't be able to progress to the LifeScienceXchange platform.